Since apoptotic liver injury triggers fibrosis, which is a major factor of mortality in NAFLD and thus represents an important end point in clinical NAFLD trials, we also assessed the potential role of TNFR1 inhibition in liver fibrosis. This evidence concerns the gene TNFRSF1A and metabolic dysfunction-associated steatotic liver disease.